Clinical Impact on Fractional Flow Reserve in Chronic Total Occlusion-Percutaneous Coronary Intervention; A Multicenter, Prospective Study

The Catholic University of Korea, St. Vincent's Hospital0 个研究点目标入组 100 人开始时间: 待定最近更新: 2024年3月4日

适应症

试验速览

暂无简介。

•1. Nineteen years old or older, with coronary artery CTO lesions, and waiting for revascularization treatment
•2. Must agree (personally or through his/her legal guardian) with the study protocol and the clinical follow-up schedules, and must sign the informed-consent form voluntarily (This study can proceed after its approval from the IRB of each center.)
•3. With a coronary artery CTO lesion on the left anterior descending artery or the right coronary artery

•1. Currently pregnant or breastfeeding or with a possibility of such
•2. Contraindicated or hypersensitive to the contrast agent or heparin
•3. Contraindicated to aspirin, clopidogrel, cilostazol, ticagrelor, or prasugrel
•4. Scheduled to undergo operation, etc. requiring antiplatelet drugs to be stopped within 12 months from participation in the study
•5. Has had MI with an acute ST fragment rise
•6. Has a terminal disease, with a remaining life expectancy of less than 1 year
•7. Has a serious disease that can limit the remaining life expectancy or compliance with the study protocol (e.g. oxygen-dependent COPD, active hepatitis, severe liver failure, severe renal disease, or others believed by the investigator to applicable)

发起方